GSK Stock Plunges 3.21% Amid Patent Loss

GSK's stock price fell to its lowest level since January 2025 today, with an intraday decline of 3.21%.

GSK recently received FDA approval for a new urinary tract infection (UTI) treatment called Blujepa. This regulatory approval is a positive development that could impact the company's market performance. The approval of Blujepa is expected to enhance GSK's product portfolio and potentially drive revenue growth in the coming quarters.

However, GSK's respiratory syncytial virus (RSV) vaccine patents were found to be invalid. This ruling could have negative implications for the company's competitive positioning and financial performance. The invalidation of these patents may expose GSK to increased competition and potentially reduce its market share in the RSV vaccine segment.

Additionally, ABL Bio signed a $2.8 billion license-out deal with GSK. Despite the deal's significant financial value, the sentiment around this news was reported as negative, suggesting potential concerns or market skepticism. The negative market reaction to this deal could be attributed to various factors, including concerns about the long-term financial impact and the potential risks associated with the licensing agreement.